NYMX Nymox Pharmaceutical Corporation

1.6
-0.06  -4%
Previous Close 1.66
Open 1.65
Price To Book 26.67
Market Cap 101949930
Shares 63,718,706
Volume 68,350
Short Ratio
Av. Daily Volume 154,090

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
Phase 3 endpoints met in extension trial July 2015. Noted March 28, 2017 that regulatory filing is due during the next few weeks.
NX-1207 Fexapotide
BPH